Frisell T, et al. - From 2010–2016, investigators analyzed the comparative efficiency of abatacept, rituximab, tocilizumab, and TNF-inhibitors (TNFi) biologics among subjects with RA treated in Swedish clinical practice. They observed that candidates beginning with non-TNFi (vs TNFi) as the first bDMARD had a greater proportion remaining on the drug which led to most response outcomes as first bDMARD (1-year EULAR Good Response/HAQ improvement: TNFi 24.9/25.4%, rituximab 28.6/37.2%, abatacept 31.9/33.7%, tocilizumab 50.9/43.1%). They concluded that treatment outcomes were in line with superior effectiveness of non-TNFi bDMARDs, especially in tocilizumab and rituximab.